Active Ingredient History

  • Now
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of Obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.   Wikipedia

  • SMILES: COC1=CC(=N/C/1=C\c2[nH]c(C)cc2C)c3cc4ccccc4[nH]3
  • Mol. Mass: 317.39
  • ALogP: 4.49
  • ChEMBL Molecules:
More Chemistry
gx015-070 | gx 15-070 | gx-15-070 | gx15-070 | gx15-070ms | obatoclax | obatoclax mesylate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue